Skip to main content
Premium Trial:

Request an Annual Quote

Rules-Based Medicine, EMD To Co-Develop Protein Multiplex Assays for xMAP

NEW YORK (GenomeWeb News) - Rules-Based Medicine and EMD Chemicals said today that they are partnering to develop and distribute immunoassay products for use on Luminex’s xMAP platform.
 
Under the terms of the agreement, biomarker testing firm RBM is providing EMD, a subsidiary of Germany’s Merck KGaA, exclusive distribution rights to its catalog of quantitative protein multiplex assays.
 
EMD will market RBM’s testing content in co-branded multi-analyte kits under its Novagen brand.
 
The kits will be available in the middle of 2008 and will be marketed to pharmaceutical and biotechnology companies and universities.
 
The agreement follows EMD’s announcement last week that it had signed a deal with Luminex to use the xMAP platform for multiplex immunoassays.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.